DLA Piper appoints life sciences lawyer Albright to corporate and finance practice
DLA Piper has announced that Shane Albright has joined the firm’s corporate and finance practice as a partner in the Silicon Valley office.
Albright represents life sciences companies in a range of corporate and financial matters, including corporate partnering transactions, strategic alliances, technology licences and commercial contracts.
In addition, he represents companies and investors in connection with venture financings, other funding transactions and general corporate matters and frequently advises clients on licensing and commercial contract issues in connection with mergers and acquisitions, initial public offerings and other public financings.
His experience and clients span a variety of life sciences sub-specialties such as biotechnology, medical devices, diagnostics, vaccines and medical research.
Albright, who joins DLA Piper from Hogan Lovells where he was a partner, is a frequent speaker on issues relating to licensing and corporate partnering.
He earned his JD from Stanford Law School, his PhD in molecular and cell biology from the University of California, Berkeley, and his BS in biological sciences from Stanford University.
News from DLA Piper
News from The Lawyer
Briefings from DLA Piper
Be Global is DLA Piper’s snapshot of key global employment law developments designed to help you identify legal hotspots across your global operations.
The US Department of Treasury’s Office of Foreign Assets Control has issued additional sanctions targeting certain Russian banks, energy and defence companies.
Analysis from The Lawyer
Shearman & Sterling is making its presence felt in the City, squaring up to magic circle firms and looking to muscle in on key relationships. Private equity house Bridgepoint is one outfit that has had its head turned by the US firm.
A new breed of lawyer is smoothing the path for companies entering emerging or unstable jurisdictions